NANOVIRICIDES INC (NNVC) Stock Price, Forecast & Analysis
USA - NYSEARCA:NNVC - US6300873022 - Common Stock
NNVC Key Statistics, Chart & Performance
The current stock price of NNVC is 1.46 USD. In the past month the price decreased by -3.95%. In the past year, price increased by 8.96%.
NNVC Latest News, Press Relases and Analysis
NNVC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About NNVC
Company Profile
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Company Info
NANOVIRICIDES INC
1 Controls Drive
Shelton CONNECTICUT 06484 US
CEO: Anil Diwan
Employees: 7
Phone: 12036685580
NANOVIRICIDES INC / NNVC FAQ
What does NNVC do?
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
What is the stock price of NANOVIRICIDES INC today?
The current stock price of NNVC is 1.46 USD. The price increased by 2.82% in the last trading session.
Does NNVC stock pay dividends?
NNVC does not pay a dividend.
What is the ChartMill rating of NANOVIRICIDES INC stock?
NNVC has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists NNVC stock?
NNVC stock is listed on the NYSE Arca exchange.
What is the Price/Earnings (PE) ratio of NANOVIRICIDES INC (NNVC)?
NANOVIRICIDES INC (NNVC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
Can you provide the ownership details for NNVC stock?
You can find the ownership structure of NANOVIRICIDES INC (NNVC) on the Ownership tab.
NNVC Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NNVC. When comparing the yearly performance of all stocks, NNVC turns out to be only a medium performer in the overall market: it outperformed 67.76% of all stocks.
NNVC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NNVC. While NNVC seems to be doing ok healthwise, there are quite some concerns on its profitability.
NNVC Financial Highlights
Over the last trailing twelve months NNVC reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 9.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -107.29% | ||
| ROE | -125.93% | ||
| Debt/Equity | 0 |
NNVC Forecast & Estimates
7 analysts have analysed NNVC and the average price target is 7.14 USD. This implies a price increase of 389.04% is expected in the next year compared to the current price of 1.46.